Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

Abbi KK, Rybka W, Ehmann WC, Claxton DF (2015) Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia. Clin Lymphoma Myeloma Leuk 15:41–46PubMedCrossRef

Abramson JS, Takvorian RW, Fisher DC, Feng Y, Jacobsen ED, Brown JR, Barnes JA, Neuberg DS, Hochberg EP (2013) Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study. Leuk Lymphoma 54:1915–1920PubMedPubMedCentralCrossRef

Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, Miragliuolo A, Guarrasi R, Lanna M, Cennamo G, Faiola V, Del Prete S (2010) Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 28:543–548PubMedCrossRef

Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims MP, Stiff PJ, Appelbaum FR (2010) Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol 151:430–434PubMedPubMedCentralCrossRef

Agura E, Cooper B, Holmes H, Vance E, Berryman RB, Maisel C, Li S, Saracino G, Tadic-Ovcina M, Fay J (2011) Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist 16:197–206PubMedPubMedCentralCrossRef

Albert DA, Gudas LJ (1985) Ribonucleotide reductase activity and deoxyribonucleoside triphosphate metabolism during the cell cycle of S49 wild-type and mutant mouse T-lymphoma cells. J Biol Chem 260:679–684PubMed

Amato DA, Bruckner H, Dt Guerry, Ash A, Falkson G, Borden EC, Creech RH, Savlov ED, Cunningham TJ (1987) Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma. Invest New Drugs 5:293–297PubMedCrossRef

Amato RJ, Jac J, Hernandez-McClain J (2008) Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results. Clin Genitourin Cancer 6:73–78PubMedCrossRef

Anger B, Porzsolt F, Leichtle R, Heinze B, Bartram C, Heimpel H (1989) A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. Blut 58:275–278PubMedCrossRef

Archimbaud E, Troncy J, Sebban C, Guyotat D, Devaux Y, French M, Moriceau M, Viala JJ, Fiere D (1989) Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia. Cancer Chemother Pharmacol 25:223–225PubMedCrossRef

Avolio TM, Lee Y, Feng N, Xiong K, Jin H, Wang M, Vassilakos A, Wright J, Young A (2007) RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo. Anticancer Drugs 18:377–388PubMedCrossRef

Axelson JA, Clark RH, Dimitrov NV (1987) cis-Platinum, 5-fluorouracil, and hydroxyurea in the treatment of advanced non-small-cell lung cancer. A phase II study. Am J Clin Oncol 10:243–244PubMedCrossRef

Aye Y, Li M, Long MJ, Weiss RS (2015) Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. Oncogene 34:2011–2021PubMedCrossRef

Baker CH, Banzon J, Bollinger JM, Stubbe J, Samano V, Robins MJ, Lippert B, Jarvi E, Resvick R (1991) 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 34:1879–1884PubMedCrossRef

Barr PM, Fu P, Lazarus HM, Horvath N, Gerson SL, Koc ON, Bahlis NJ, Snell MR, Dowlati A, Cooper BW (2009) Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. Br J Haematol 147:89–96PubMedPubMedCentralCrossRef

Baselga J, Kris MG, Scher HI, Phillips M, Heelan RT (1993) Phase II trial of gallium nitrate in previously treated patients with small cell lung cancer. Invest New Drugs 11:85–86PubMedCrossRef

Beck WS, Goulian M, Larsson A, Reichard P (1966) Hydrogen donor specificity of cobamide-dependent ribonucleotide reductase and allosteric regulation of substrate specificity. J Biol Chem 241:2177–2179PubMed

Beitler JJ, Smith RV, Haynes H, Silver CE, Quish A, Kotz T, Serrano M, Brook A, Wadler S (1998) A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck. Invest New Drugs 16:161–169PubMedCrossRef

Belani CP, Eisenberger M, Van Echo D, Hiponia D, Aisner J (1987) Phase II study of caracemide in advanced or recurrent non-small cell lung cancer. Cancer Treat Rep 71:1099–1100PubMed

Bendell JC, Eder JP, Clark JW, Fidias P, Lynch TJ, Seiden MV, Ryan DP (2005) Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors. Cancer 103:1925–1931PubMedCrossRef

Bernstein LR (1998) Mechanisms of therapeutic activity for gallium. Pharmacol Rev 50:665–682PubMed

Bernstein LR, van der Hoeven JJ, Boer RO (2011) Hepatocellular carcinoma detection by gallium scan and subsequent treatment by gallium maltolate: rationale and case study. Anticancer Agents Med Chem 11:585–590PubMedCrossRef

Bhalla K, Birkhofer M, Bhalla M, Lutzky J, Hindenburg A, Cole J, Ince C (1991) A phase I study of a combination of allopurinol, 5-fluorouracil and leucovorin followed by hydroxyurea in patients with advanced gastrointestinal and breast cancer. Am J Clin Oncol 14:509–513PubMedCrossRef

Bickers JN (1964) Phase II studies of hydroxyurea (NSC-32065) in adults: carcinoma of the lung. Cancer Chemother Rep 40:45–46PubMed

Blakley RL (1965) Cobamides and ribonucleotide reduction. I. cobamide stimulation of ribonucleotide reduction in extracts of Lactobacillus Leichmannii. J Biol Chem 240:2173–2180PubMed

Blumenthal GM, Scher NS, Cortazar P, Chattopadhyay S, Tang S, Song P, Liu Q, Ringgold K, Pilaro AM, Tilley A, King KE, Graham L, Rellahan BL, Weinberg WC, Chi B, Thomas C, Hughes P, Ibrahim A, Justice R, Pazdur R (2013) First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Clin Cancer Res 19:4911–4916PubMedCrossRef

Bolton BH, Kaung DT, Lawton RL, Woods LA (1964) Hydroxyurea (NSC-32065)—a phase I study. Cancer Chemother Rep 39:47–51PubMed

Brachman DG, Pugh SL, Ashby LS, Thomas TA, Dunbar EM, Narayan S, Robins HI, Bovi JA, Rockhill JK, Won M, Curran WP (2015) Phase 1/2 trials of temozolomide, motexafin gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513. Int J Radiat Oncol Biol Phys 91:961–967PubMedPubMedCentralCrossRef

Bradley KA, Pollack IF, Reid JM, Adamson PC, Ames MM, Vezina G, Blaney S, Ivy P, Zhou T, Krailo M, Reaman G, Mehta MP (2008) Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children’s Oncology Group phase I study. Neuro Oncol 10:752–758PubMedPubMedCentralCrossRef

Brockman RW, Schabel FM Jr, Montgomery JA (1977) Biologic activity of 9-beta-d-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-beta-d-arabinofuranosyladenine. Biochem Pharmacol 26:2193–2196PubMedCrossRef

Brockstein B, Haraf DJ, Stenson K, Fasanmade A, Stupp R, Glisson B, Lippman SM, Ratain MJ, Sulzen L, Klepsch A, Weichselbaum RR, Vokes EE (1998) Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol 16:735–744PubMedCrossRef

Brooks DJ, Cox J, Berman BS, Amare M, Benson AB, Masuoka L, Klencke B (2003) Phase 2 study of tezacitabine in subjects with advanced/recurrent colorectal cancer. Proc Am Soc Clin Oncol 22:279

Burtness B, Belker M, Stoltz M, Peccerillo KM, Lamb LA, Chmael SE, McKeon A, Clark MB, Winship J, Marsh JC, Pizzorno G, DeVita VT Jr (2000) A phase I study of the antimetabolite (E)-2′-fluoromethylene-2′-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion. Cancer J 6:309–315PubMed

Canfield VA, Lyss AP (1993) A phase II trial of gallium nitrate in advanced previously untreated colorectal cancer. Invest New Drugs 11:335–336PubMedCrossRef

Carde P, Timmerman R, Mehta MP, Koprowski CD, Ford J, Tishler RB, Miles D, Miller RA, Renschler MF (2001) Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 19:2074–2083PubMedCrossRef

Carmichael J, Cantwell BM, Mannix KA, Veale D, Elford HL, Blackie R, Kerr DJ, Kaye SB, Harris AL (1990) A phase I and pharmacokinetic study of didox administered by 36 hour infusion. The Cancer Research Campaign Phase I/II Clinical Trials Committee. Br J Cancer 61:447–450PubMedPubMedCentralCrossRef

Casper ES, Stanton GF, Sordillo PP, Parente R, Michaelson RA, Vinceguerra V (1985) Phase II trial of gallium nitrate in patients with advanced malignant melanoma. Cancer Treat Rep 69:1019–1020PubMed

Catapano CV, Chandler KB, Fernandes DJ (1991) Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate. Cancer Res 51:1829–1835PubMed

Catimel G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweij J, Wanders J et al (1994) A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5:543–547PubMedCrossRef

Cerqueira NM, Fernandes PA, Ramos MJ (2007) Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents. Recent Pat Anticancer Drug Discov 2:11–29PubMed

Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Schneeweiss A, Lluch A, Llombart A, du Bois A, Kreienberg R, Mayordomo JI, Anton A, Harrison M, Jones A, Carrasco E, Vaury AT, Frimodt-Moller B, Fumoleau P (2009) Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 27:1753–1760PubMedCrossRef

Chang AY, Tu ZN, Smith JL, Bonomi P, Smith TJ, Wiernik PH, Blum R (1995) Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588). Invest New Drugs 13:137–141PubMedCrossRef

Chapman TR, Kinsella TJ (2011) Ribonucleotide reductase inhibitors: a new look at an old target for radiosensitization. Front Oncol 1:56PubMed

Charache S, Terrin ML, Moore RD, Dover GJ, McMahon RP, Barton FB, Waclawiw M, Eckert SV (1995) Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea. Control Clin Trials 16:432–446PubMedCrossRef

Chitambar CR, Purpi DP (2010) A novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma cells. Leuk Res 34:950–953PubMedPubMedCentralCrossRef

Chitambar CR, Narasimhan J, Guy J, Sem DS, O’Brien WJ (1991) Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells. Cancer Res 51:6199–6201PubMed

Chitambar CR, Purpi DP, Woodliff J, Yang M, Wereley JP (2007) Development of gallium compounds for treatment of lymphoma: gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate. J Pharmacol Exp Ther 322:1228–1236PubMedCrossRef

Chua MS, Bernstein LR, Li R, So SK (2006) Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma. Anticancer Res 26:1739–1743PubMed

Cohen MH, Johnson JR, Pazdur R (2005) U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 11:12–19PubMed

Cory JG, Cory AH, Rappa G, Lorico A, Liu MC, Lin TS, Sartorelli AC (1995) Structure-function relationships for a new series of pyridine-2-carboxaldehyde thiosemicarbazones on ribonucleotide reductase activity and tumor cell growth in culture and in vivo. Adv Enzyme Regul 35:55–68PubMedCrossRef

Crawford ED, Saiers JH, Baker LH, Costanzi JH, Bukowski RM (1991) Gallium nitrate in advanced bladder carcinoma: southwest Oncology Group study. Urology 38:355–357PubMedCrossRef

Currie JL, Blessing JA, McGehee R, Soper JT, Berman M (1996) Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 61:94–96PubMedCrossRef

Davis P (1964) Phase II studies of hydroxyurea (NSC-32065) in adults: multiple myeloma and lymphoma. Cancer Chemother Rep 40:51–52PubMed

Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6:659–668PubMedCrossRef

Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067–1070PubMedPubMedCentralCrossRef

De Vita F, Ventriglia J, Febbraro A, Laterza MM, Fabozzi A, Savastano B, Petrillo A, Diana A, Giordano G, Troiani T, Conzo G, Galizia G, Ciardiello F, Orditura M (2016) NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. BMC Cancer 16:709PubMedPubMedCentralCrossRef

Desai AA, Schilsky RL, Young A, Janisch L, Stadler WM, Vogelzang NJ, Cadden S, Wright JA, Ratain MJ (2005) A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol 16:958–965PubMedCrossRef

Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA (2007) Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 83:53–60PubMedCrossRef

Dodion P, Cognetti F, van Rymenant M, Dalesio O, Kirkpatrick A, Rozencweig M (1986) Phase II study of a combination of hydroxyurea, fluorouracil and mitomycin in previously treated squamous cell carcinoma of the head and neck. Eur J Cancer Clin Oncol 22:241–243PubMedCrossRef

Dreicer R, Propert KJ, Roth BJ, Einhorn LH, Loehrer PJ (1997) Vinblastine, ifosfamide, and gallium nitrate–an active new regimen in patients with advanced carcinoma of the urothelium. A phase II trial of the Eastern Cooperative Oncology Group (E5892). Cancer 79:110–114PubMedCrossRef

Dreicer R, Lallas TA, Joyce JK, Anderson B, Sorosky JI, Buller RE (1998) Vinblastine, ifosfamide, gallium nitrate, and filgrastim in platinum- and paclitaxel-resistant ovarian cancer: a phase II study. Am J Clin Oncol 21:287–290PubMedCrossRef

Dresemann G, Weller M, Rosenthal MA, Wedding U, Wagner W, Engel E, Heinrich B, Mayer-Steinacker R, Karup-Hansen A, Fluge O, Nowak A, Mehdorn M, Schleyer E, Krex D, Olver IN, Steinbach JP, Hosius C, Sieder C, Sorenson G, Parker R, Nikolova Z (2010) Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol 96:393–402PubMedCrossRef

du Bois A, Herrstedt J, Hardy-Bessard AC, Muller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J (2010) Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 28:4162–4169PubMedCrossRef

Dubowy R, Graham M, Hakami N, Kletzel M, Mahoney D, Newman E, Ravindranath Y, Camitta B (2008) Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study. J Pediatr Hematol Oncol 30:353–357PubMedPubMedCentralCrossRef

Duenas-Gonzalez A, Zarba JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H, Orlando M (2011) Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 29:1678–1685PubMedCrossRef

Duffy A, Kortmansky J, Schwartz GK, Capanu M, Puleio S, Minsky B, Saltz L, Kelsen DP, O’Reilly EM (2008) A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 19:86–91PubMedCrossRef

Edelman MJ, Otterson G, Leach J, Malpass T, Salgia R, Jones D, Mody TD, Govindan R (2011) Multicenter phase II trial of motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. J Thorac Oncol 6:786–789PubMedCrossRef

Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jager U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Dohner H, Brittinger G, Emmerich B, Hallek M, German CLLSG (2006) Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885–891PubMedCrossRef

Eklund H, Eriksson M, Uhlin U, Nordlund P, Logan D (1997) Ribonucleotide reductase–structural studies of a radical enzyme. Biol Chem 378:821–825PubMed

Elford HL, Wampler GL, van’t Riet B (1979) New ribonucleotide reductase inhibitors with antineoplastic activity. Cancer Res 39:844–851PubMed

Elledge SJ, Zheng Z, Allen JB (1992) Ribonucleotide reductase—regulation, regulation, regulation. Trends Biochem Sci 17:119–123PubMedCrossRef

Engstrom PF, MacIntyre JM, Douglass HO Jr, Muggia F, Mittelman A (1982) Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275). Cancer 49:1555–1560PubMedCrossRef

Evens AM (2004) Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. Curr Opin Oncol 16:576–580PubMedCrossRef

Evens AM, Lecane P, Magda D, Prachand S, Singhal S, Nelson J, Miller RA, Gartenhaus RB, Gordon LI (2005) Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. Blood 105:1265–1273PubMedCrossRef

Evens AM, Spies WG, Helenowski IB, Patton D, Spies S, Jovanovic BD, Miyata S, Hamilton E, Variakojis D, Chen J, Naumovski L, Rosen ST, Winter JN, Miller RA, Gordon LI (2009) The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin’s lymphoma: preclinical findings and results of a phase I trial. Clin Cancer Res 15:6462–6471PubMedPubMedCentralCrossRef

Fabian CJ, Baker LH, Vaughn CB, Hynes HE (1982) Phase II evaluation of gallium nitrate in breast cancer: a Southwest Oncology Group Study. Cancer Treat Rep 66:1591PubMed

Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM (2012) Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol 30:2492–2499PubMedPubMedCentralCrossRef

Fairman JW, Wijerathna SR, Ahmad MF, Xu H, Nakano R, Jha S, Prendergast J, Welin RM, Flodin S, Roos A, Nordlund P, Li Z, Walz T, Dealwis CG (2011) Structural basis for allosteric regulation of human ribonucleotide reductase by nucleotide-induced oligomerization. Nat Struct Mol Biol 18:316–322PubMedPubMedCentralCrossRef

Fan H, Villegas C, Wright JA (1996) Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci USA 93:14036–14040PubMedPubMedCentralCrossRef

Farag SS, Wood LL, Schwartz JE, Srivastava S, Nelson RP Jr, Robertson MJ, Abonour R, Secrest A, Cox E, Baute J, Sullivan C, Kane K, Jones DR (2011) Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia. Leukemia 25:599–605PubMedCrossRef

Fidias P, Chabner BA, Grossbard ML (1996) Purine analogs for the treatment of low-grade lymphoproliferative disorders. Oncologist 1:125–139PubMed

Figul M, Soling A, Dong HJ, Chou TC, Rainov NG (2003) Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells. Cancer Chemother Pharmacol 52:41–46PubMedCrossRef

Finch RA, Liu M, Grill SP, Rose WC, Loomis R, Vasquez KM, Cheng Y, Sartorelli AC (2000) Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol 59:983–991PubMedCrossRef

Flaherty KT, Stevenson JP, Gallagher M, Giantonio B, Algazy KM, Sun W, Haller DG, O’Dwyer PJ (2003) Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer. Cancer 97:1985–1990PubMedCrossRef

Fontecave M, Gerez C, Mansuy D, Reichard P (1990) Reduction of the Fe(III)-tyrosyl radical center of Escherichia coli ribonucleotide reductase by dithiothreitol. J Biol Chem 265:10919–10924PubMed

Foran JM (2014) Clofarabine or daunorubicin hydrochloride and cytarabine followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia. ClinicalTrials.gov Identifier:NCT02085408, https://clinicaltrials.gov/ct2/show/NCT02085408. Accessed 6 June 2017.

Ford JM, Seiferheld W, Alger JR, Wu G, Endicott TJ, Mehta M, Curran W, Phan SC (2007) Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 69:831–838PubMedCrossRef

Fritzer-Szekeres M, Novotny L, Romanova D, Gobl R, Sedlak J, Vachalkova A, Rauko P, Elford HL, Szekeres T (1998) Enhanced effects of adriamycin by combination with a new ribonucleotide reductase inhibitor, trimidox, in murine leukemia. Life Sci 63:545–552PubMedCrossRef

Fritzer-Szekeres M, Grusch M, Luxbacher C, Horvath S, Krupitza G, Elford HL, Szekeres T (2000) Trimidox, an inhibitor of ribonucleotide reductase, induces apoptosis and activates caspases in HL-60 promyelocytic leukemia cells. Exp Hematol 28:924–930PubMedCrossRef

Fritzer-Szekeres M, Salamon A, Grusch M, Horvath Z, Hochtl T, Steinbrugger R, Jager W, Krupitza G, Elford HL, Szekeres T (2002) Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol 64:481–485PubMedCrossRef

Gandhi V, Plunkett W (2002) Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 41:93–103PubMedCrossRef

Gandhi V, Robertson LE, Keating MJ, Plunkett W (1994) Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol 34:30–36PubMedCrossRef

Garbo LE, Flynn PJ, MacRae MA, Rauch MA, Wang Y, Kolibaba KS (2009) Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma. Invest New Drugs 27:476–481PubMedCrossRef

Garcia-Del-Muro X, Lopez-Pousa A, Maurel J, Martin J, Martinez-Trufero J, Casado A, Gomez-Espana A, Fra J, Cruz J, Poveda A, Meana A, Pericay C, Cubedo R, Rubio J, De Juan A, Lainez N, Carrasco JA, de Andres R, Buesa JM (2011) Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas Study. J Clin Oncol 29:2528–2533PubMedCrossRef

Gebbia V, Maiello E, Serravezza G, Giotta F, Testa A, Borsellino N, Pezzella G, Colucci G (1999) 5-Fluorouracil plus high dose levofolinic acid and oral hydroxyurea for the treatment of primary hepatocellular carcinomas: results of a phase II multicenter study of the Southern Italy Oncology Group (G.O.I.M.). Anticancer Res 19:1407–1410PubMed

Genini D, Adachi S, Chao Q, Rose DW, Carrera CJ, Cottam HB, Carson DA, Leoni LM (2000) Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 96:3537–3543PubMed

Geyer JR, Zeltzer PM, Boyett JM, Rorke LB, Stanley P, Albright AL, Wisoff JH, Milstein JM, Allen JC, Finlay JL et al (1994) Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group. J Clin Oncol 12:1607–1615PubMedCrossRef

Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF, Gandhi V (2003) Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res 27:1077–1083PubMedCrossRef

Glick JH, Zehngebot LM, Taylor SG (1980) Chemotherapy for squamous cell carcinoma of the head and neck: a progress report. Am J Otolaryngol 1:306–323PubMedCrossRef

Gojo I, Tidwell ML, Greer J, Takebe N, Seiter K, Pochron MF, Johnson B, Sznol M, Karp JE (2007) Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res 31:1165–1173PubMedCrossRef

Graham DL, Hillman DW, Hobday TJ (2005) N0234: phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol. 23:Abstr. 644CrossRef

Griffig J, Koob R, Blakley RL (1989) Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res 49:6923–6928PubMed

Griffith KM (1964) Hydroxyurea (NSC-32065): results of a phase I study. Cancer Chemother Rep 40:33–36PubMed

Guo JR, Chen QQ, Lam CW, Wang CY, Wong VK, Chang ZF, Zhang W (2016) Profiling ribonucleotide and deoxyribonucleotide pools perturbed by gemcitabine in human non-small cell lung cancer cells. Sci Rep 6:37250PubMedPubMedCentralCrossRef

Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, MacLennan K, Staab-Renner E, Kalmus J, Schott A, Teodorovic I, Negrouk A, van Glabbeke M, Marcus R (2006) Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin’s lymphoma. J Clin Oncol 24:1590–1596PubMedCrossRef

Halim AA, Wahba HA, El-Hadaad HA, Abo-Elyazeed A (2011) Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: a phase III study. Med Oncol 29:279–284PubMedCrossRef

Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164–1174PubMedCrossRef

Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33–45PubMedCrossRef

Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, Hasford J, Reiter A, Hossfeld DK, Kolb HJ, Loffler H, Pralle H, Queisser W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiss J, Meier CR, Kremers S, Labedzki L, Schmeiser T, Lohrmann HP, Heimpel H (2003) Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia 17:1529–1537PubMedCrossRef

Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME (2007) Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA 104:5715–5721PubMedPubMedCentralCrossRef

Higashi T, Wakao H, Yamaguchi M, Suga K (1988) The relationship between Ga-67 accumulation and cell cycle in malignant tumor cells in vitro. Eur J Nucl Med 14:155–158PubMedCrossRef

Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R, Cooper T, Kadota R, Rytting M, Steinherz P, Shen V, Jeha S, Abichandani R, Carroll WL (2009) A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia 23:2259–2264PubMedCrossRef

Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, Skotnicki A, Jedrzejczak WW, Konopka L, Kuliczkowski K, Zdziarska B, Dmoszynska A, Marianska B, Pluta A, Zawilska K, Komarnicki M, Kloczko J, Sulek K, Haus O, Stella-Holowiecka B, Baran W, Jakubas B, Paluszewska M, Wierzbowska A, Kielbinski M, Jagoda K (2004) Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 18:989–997PubMedCrossRef

Horvath Z, Bauer W, Hoechtl T, Saiko P, Fritzer-Szekeres M, Tihan T, Szekeres T (2004a) Combination chemotherapy of BCNU and didox acts synergistically in 9L glioma cells. Nucleosides Nucleotides Nucleic Acids 23:1531–1535PubMedCrossRef

Horvath Z, Hochtl T, Bauer W, Fritzer-Szekeres M, Elford HL, Szekeres T, Tihan T (2004b) Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells. Cancer Chemother Pharmacol 54:139–145PubMedCrossRef

Howe CD, Samuels ML (1964) Phase II Studies Of Hydroxyurea (NSC-32065) in adults: urologic and gynecologic neoplasms. Cancer Chemother Rep 40:47–48PubMed

Huang P, Chubb S, Plunkett W (1990) Termination of DNA synthesis by 9-beta-d-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem 265:16617–16625PubMed

Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110–6117PubMed

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRef

Inayat MS, Chendil D, Mohiuddin M, Elford HL, Gallicchio VS, Ahmed MM (2002) Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3. Cancer Biol Ther 1:539–545PubMedCrossRef

Itani Y, Hosokawa K, Ito K, Takeuchi S, Tabata T, Tsubamoto H, Fujita H, Akiyama M, Adachi S (2009) A phase I/II study of docetaxel and gemcitabine combination for chemotherapy-resistant ovarian cancer. Anticancer Res 29:1521–1526PubMed

Iyamu WE, Adunyah SE, Fasold H, Horiuchi K, Elford HL, Asakura T, Turner EA (2000) Enhancement of hemoglobin and F-cell production by targeting growth inhibition and differentiation of K562 cells with ribonucleotide reductase inhibitors (didox and trimidox) in combination with streptozotocin. Am J Hematol 63:176–183PubMedCrossRef

Jabboury K, Frye D, Holmes FA, Fraschini G, Hortobagyi G (1989) Phase II evaluation of gallium nitrate by continuous infusion in breast cancer. Invest New Drugs 7:225–229PubMedCrossRef

Jager G, Neumeister P, Brezinschek R, Hinterleitner T, Fiebiger W, Penz M, Neumann HJ, Mlineritsch B, DeSantis M, Quehenberger F, Chott A, Beham-Schmid C, Hofler G, Linkesch W, Raderer M (2002) Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol 20:3872–3877PubMedCrossRef

Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman S, Steinherz P (2006) Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 24:1917–1923PubMedCrossRef

Jeha S, Razzouk B, Rytting M, Rheingold S, Albano E, Kadota R, Luchtman-Jones L, Bomgaars L, Gaynon P, Goldman S, Ritchey K, Arceci R, Altman A, Stine K, Steinherz L, Steinherz P (2009) Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol 27:4392–4397PubMedPubMedCentralCrossRef

Jehn U, Gawaz M, Grunewald R, Hill W, Lorenz B, Stotzer O (1993) Successful treatment of patients with hairy cell leukemia (HCL) using a single cycle of 2-chloro-2′-deoxyadenosine (CdA). Anticancer Res 13:1809–1814PubMed

Jordan A, Pontis E, Atta M, Krook M, Gibert I, Barbe J, Reichard P (1994) A second class I ribonucleotide reductase in Enterobacteriaceae: characterization of the Salmonella typhimurium enzyme. Proc Natl Acad Sci USA 91:12892–12896PubMedPubMedCentralCrossRef

Juliusson G, Elmhorn-Rosenborg A, Liliemark J (1992) Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 327:1056–1061PubMedCrossRef

Kanazawa J, Takahashi T, Akinaga S, Tamaoki T, Okabe M (1998) The relationship between the antitumor activity and the ribonucleotide reductase inhibitory activity of (E)-2′-deoxy-2′-(fluoromethylene) cytidine, MDL 101,731. Anticancer Drugs 9:653–657PubMedCrossRef

Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R (2007) Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 13:5291–5294PubMedCrossRef

Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O’Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M (2003) Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 21:1167–1173PubMedCrossRef

Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M, Petersdorf S, Shami PJ, Yeager AM, Eckert S, Abichandani R, Faderl S (2010) Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 28:549–555PubMedCrossRef

Kao J, Genden EM, Gupta V, Policarpio EL, Burri RJ, Rivera M, Gurudutt V, Som PM, Teng M, Packer SH (2011) Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer. Cancer 117:318–326PubMedCrossRef

Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD, Smith BD, McDevitt MA, Carraway H, Levis MJ, Gandhi V (2007) A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 110:1762–1769PubMedPubMedCentralCrossRef

Karp JE, Giles FJ, Gojo I, Morris L, Greer J, Johnson B, Thein M, Sznol M, Low J (2008) A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. Leuk Res 32:71–77PubMedCrossRef

Kaubisch A, Kaleya R, Haynes H, Rozenblit A, Wadler S (2004) Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. Cancer Chemother Pharmacol 53:337–340PubMedCrossRef

Keating MJ, Estey E, O’Brien S, Kantarjian H, Robertson LE, Plunkett W (1994a) Clinical experience with fludarabine in leukaemia. Drugs 47(Suppl 6):39–49PubMedCrossRef

Keating MJ, O’Brien S, Plunkett W, Robertson LE, Gandhi V, Estey E, Dimopoulos M, Cabanillas F, Kemena A, Kantarjian H (1994b) Fludarabine phosphate: a new active agent in hematologic malignancies. Semin Hematol 31:28–39PubMed

Keller J, Bartolucci A, Carpenter JT Jr, Feagler J (1986) Phase II evaluation of bolus gallium nitrate in lymphoproliferative disorders: a Southeastern Cancer Study Group trial. Cancer Treat Rep 70:1221–1223PubMed

Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan K, Marcucci G (2008) Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. Clin Cancer Res 14:3889–3895PubMedPubMedCentralCrossRef

Knox JJ, Hotte SJ, Kollmannsberger C, Winquist E, Fisher B, Eisenhauer EA (2007) Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). Invest New Drugs 25:471–477PubMedCrossRef

Ko Y, North S, Berry SR, Ernst DS, Klotz L, Murray P, Venner P (2006) Dose escalation phase of a phase I/II study of GTI-2501, an antisense to the R1 subunit of ribonucleotide reductase (RNR) and docetaxel in patients with metastatic hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 24:2078

Kolberg M, Strand KR, Graff P, Andersson KK (2004) Structure, function, and mechanism of ribonucleotide reductases. Biochem Biophys Acta 1699:1–34PubMed

Kouroukis CT, Fernandez LA, Crump M, Gascoyne RD, Chua NS, Buckstein R, Turner R, Assouline S, Klasa RJ, Walsh W, Powers J, Eisenhauer E (2011) A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk Lymphoma 52:394–399PubMedCrossRef

Krakoff IH (1991) Gallium nitrate in the treatment of cancer-related hypercalcemia. Semin Oncol 18:3PubMed

Krakoff IH, Newman RA, Goldberg RS (1979) Clinical toxicologic and pharmacologic studies of gallium nitrate. Cancer 44:1722–1727PubMedCrossRef

Lad T, Schor J, Mullane M, Carroll R, Chernicoff D, Blough R, Weidner L (1992) Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study. Invest New Drugs 10:27–28PubMedCrossRef

Lang P, Teltschik HM, Feuchtinger T, Muller I, Pfeiffer M, Schumm M, Ebinger M, Schwarze CP, Gruhn B, Schrauder A, Albert MH, Greil J, Urban C, Handgretinger R (2014) Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia. Br J Haematol 165:688–698PubMedCrossRef

Larsen IK, Cornett C, Karlsson M, Sahlin M, Sjoberg BM (1992) Caracemide, a site-specific irreversible inhibitor of protein R1 of Escherichia coli ribonucleotide reductase. J Biol Chem 267:12627–12631PubMed

Lazzarino M, Morra E, Brusamolino E, Alessandrino EP, Orlandi E, Pagnucco G, Castagnola C, Bernasconi P, Merante S, Bonfichi M et al (1991) Treatment of terminal-phase chronic myelogenous leukemia with intermediate-dose cytarabine and hydroxyurea. Hematol Oncol 9:299–305PubMedCrossRef

Lee Y, Vassilakos A, Feng N, Lam V, Xie H, Wang M, Jin H, Xiong K, Liu C, Wright J, Young A (2003) GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res 63:2802–2811PubMed

Lee Y, Vassilakos A, Feng N, Jin H, Wang M, Xiong K, Wright J, Young A (2006) GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors. Int J Oncol 28:469–478PubMed

Leighl NB, Laurie SA, Chen XE, Ellis P, Shepherd FA, Knox JJ, Goss G, Burkes RL, Pond GR, Dick C, Yen Y, Zwiebel JA, Moore MJ (2009) A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium. J Thorac Oncol 4:1163–1169PubMedPubMedCentralCrossRef

Lerner HJ, Beckloff GL, Godwin MC (1970) Phase II study of hydroxyurea administered intermittently in malignant melanoma. Am Surg 36:505–508PubMed

Levin VA, Wilson CB, Davis R, Wara WM, Pischer TL, Irwin L (1979) A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas. J Neurosurg 51:526–532PubMedCrossRef

Levin VA, Wara WM, Davis RL, Vestnys P, Resser KJ, Yatsko K, Nutik S, Gutin PH, Wilson CB (1985) Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg 63:218–223PubMedCrossRef

Levin VA, Phuphanich S, Liu HC, Da Silva V, Murovic J, Choucair A, Chamberlain M, Berger M, Seager M, Davis RL et al (1986) Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. Cancer Treat Rep 70:1271–1274PubMed

Licht S, Gerfen GJ, Stubbe J (1996) Thiyl radicals in ribonucleotide reductases. Science 271:477–481PubMedCrossRef

Lim SH, McMahan J, Zhang J, Zhang Y (2010) A phase II study of low dose intravenous clofarabine for elderly patients with myelodysplastic syndrome who have failed 5-azacytidine. Leuk Lymphoma 51:2258–2261PubMedCrossRef

Lin TS, Naumovski L, Lecane PS, Lucas MS, Moran ME, Cheney C, Lucas DM, Phan SC, Miller RA, Byrd JC (2009) Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia. Leuk Lymphoma 50:1977–1982PubMedCrossRef

Litam PP, Landaw SA, Zamkoff KW (1994) Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease. Haematologia (Budap) 26:87–90

Lomen PL, Khilanani P, Kessel D (1980) Phase I study using combination of hydroxyurea and 5-azacytidine (NSC-102816). Neoplasma 27:101–106PubMed

Ma B, Goh BC, Tan EH, Lam KC, Soo R, Leong SS, Wang LZ, Mo F, Chan AT, Zee B, Mok T (2008) A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Invest New Drugs 26:169–173PubMedCrossRef

Malfetano JH, Blessing JA, Adelson MD (1991a) A phase II trial of gallium nitrate (NSC #15200) in previously treated ovarian carcinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol 14:349–351PubMedCrossRef

Malfetano JH, Blessing JA, Homesley HD, Hanjani P (1991b) A phase II trial of gallium nitrate (NSC #15200) in advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Invest New Drugs 9:109–111PubMedCrossRef

Malfetano JH, Blessing JA, Homesley HD (1995) A phase II trial of gallium nitrate (NSC #15200) in nonsquamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Am J Clin Oncol 18:495–497PubMedCrossRef

Manegold C, van Zandwijk N, Szczesna A, Zatloukal P, Au JS, Blasinska-Morawiec M, Serwatowski P, Krzakowski M, Jassem J, Tan EH, Benner RJ, Ingrosso A, Meech SJ, Readett D, Thatcher N (2011) A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 23:72–77PubMedCrossRef

Martin LK, Grecula J, Jia G, Wei L, Yang X, Otterson GA, Wu X, Harper E, Kefauver C, Zhou BS, Yen Y, Bloomston M, Knopp M, Ivy SP, Grever M, Bekaii-Saab T (2012) A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer. Int J Radiat Oncol Biol Phys 84:e475–e481PubMedPubMedCentralCrossRef

Mazza E, Brandes A, Zanon S, Eoli M, Lombardi G, Faedi M, Franceschi E, Reni M (2016) Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol 77:115–120PubMedCrossRef

McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF (1997) Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. J Clin Oncol 15:2449–2455PubMedCrossRef

Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, Schultz CJ, Roa WH, Leibenhaut M, Ford J, Curran W, Phan S, Smith JA, Miller RA, Renschler MF (2002) Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 20:3445–3453PubMedCrossRef

Mehta MP, Shapiro WR, Phan SC, Gervais R, Carrie C, Chabot P, Patchell RA, Glantz MJ, Recht L, Langer C, Sur RK, Roa WH, Mahe MA, Fortin A, Nieder C, Meyers CA, Smith JA, Miller RA, Renschler MF (2009) Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 73:1069–1076PubMedCrossRef

Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan SC, Miller RA, Renschler MF (2004) Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22:157–165PubMedCrossRef

Montefusco E, Fazi F, Cordone I, Ariola C, Nanni M, Spadea A, Spiriti MA, Fenu S, Mandelli F, Petti MC (2001) Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma. Leuk Lymphoma 40:671–674PubMedCrossRef

Moore EC, Loo TL (1984) Inhibition of ribonucleotide reductase by caracemide. Cancer Treat Rep 68:1293–1294PubMed

Moorthy NS, Cerqueira NM, Ramos MJ, Fernandes PA (2013) Development of ribonucleotide reductase inhibitors: a review on structure activity relationships. Mini Rev Med Chem 13:1862–1872PubMedCrossRef

Mortazavi A, Ling Y, Martin LK, Wei L, Phelps MA, Liu Z, Harper EJ, Ivy SP, Wu X, Zhou BS, Liu X, Deam D, Monk JP, Hicks WJ, Yen Y, Otterson GA, Grever MR, Bekaii-Saab T (2013) A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors. Invest New Drugs 31:685–695PubMedCrossRef

Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M (2003) Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res 9:4092–4100PubMed

Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR Jr, Marciniack M, Naumann RW, Secord AA (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811–2818PubMedCrossRef

Neri B, Vannini L, Giordano C, Grifoni R, Pantaleo P, Baldazzi V, Crisci A, Lapini A, Raugei A, Carini M (2007) Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study. Anticancer Drugs 18:1207–1211PubMedCrossRef

Novotny L, Rauko P, Liska J, Elford HL, Szekeres T (2006) Potentiation of the activity of cisplatin and cyclophosphamide by trimidox, a novel ribonucleotide reductase inhibitor, in leukemia-bearing mice. Cancer Lett 233:178–184PubMedCrossRef

Nutting CM, van Herpen CM, Miah AB, Bhide SA, Machiels JP, Buter J, Kelly C, de Raucourt D, Harrington KJ (2009) Phase II study of 3-AP triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma. Ann Oncol 20:1275–1279PubMedCrossRef

O’Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, Chanan-Khan AA, Seymour JF, Gribben J, Itri LM, Rai KR (2009) 5-Year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 27:5208–5212PubMedPubMedCentralCrossRef

O’Byrne KJ, Philip PA, Propper DJ, Braybrooke JP, Saunders MP, Bates NP, Taylor MA, Madigan D, Ganesan TS, Talbot DC, Harris AL (1999) A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma. Ann Oncol 10:981–983PubMedCrossRef

Odenike OM, Sobecks RM, Janisch L, Huo D, Zimmerman TM, Daugherty CK, Ratain MJ, Larson RA (2004) A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. Cancer Chemother Pharmacol 54:553–561PubMedCrossRef

Odenike OM, Larson RA, Gajria D, Dolan ME, Delaney SM, Karrison TG, Ratain MJ, Stock W (2008) Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs 26:233–239PubMedPubMedCentralCrossRef

Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277PubMedCrossRef

Ogura M, Morishima Y, Kobayashi Y, Uike N, Sugai S, Chou T, Kasai M, Miura I, Murayama T, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Tobinai K (2004) Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin’s lymphomas: results of a Japanese phase II study. Int J Hematol 80:267–277PubMedCrossRef

O’Shaughnessy JA, Vukelja S, Marsland T, Kimmel G, Ratnam S, Pippen JE (2004) Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 5:142–147PubMedCrossRef

Parker WB, Shaddix SC, Chang CH, White EL, Rose LM, Brockman RW, Shortnacy AT, Montgomery JA, Secrist JA 3rd, Bennett LL Jr (1991) Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 51:2386–2394PubMed

Paulsson J, Lindh MB, Jarvius M, Puputti M, Nister M, Nupponen NN, Paulus W, Soderberg O, Dresemann G, von Deimling A, Joensuu H, Ostman A, Hasselblatt M (2011) Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. Int J Cancer 128:1981–1988PubMedCrossRef

Pazdur R, Chabot GG, Baker LH (1987) Phase I study and pharmacokinetics of caracemide (NSC-253272) administered as a short infusion. Invest New Drugs 5:365–371PubMedCrossRef

Persson AL, Eriksson M, Katterle B, Potsch S, Sahlin M, Sjoberg BM (1997) A new mechanism-based radical intermediate in a mutant R1 protein affecting the catalytically essential Glu441 in Escherichia coli ribonucleotide reductase. J Biol Chem 272:31533–31541PubMedCrossRef

Petrioli R, Roviello G, Fiaschi AI, Laera L, Marrelli D, Roviello F, Francini E (2015) Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study. Cancer Chemother Pharmacol 75:683–690PubMedCrossRef

Pfisterer J, Vergote I, Du Bois A, Eisenhauer E (2005) Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 15(Suppl 1):36–41PubMedCrossRef

Philip PA, Carmichael J, Tonkin K, Ganesan TA, Harris AL (1994) A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma. Eur J Cancer 30A:1027–1029PubMedCrossRef

Piro LD, Carrera CJ, Carson DA, Beutler E (1990) Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117–1121PubMedCrossRef

Platt OS (2008) Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 358:1362–1369PubMedCrossRef

Raber MN, Adams F, Kavanagh J, Legha S, Dimery I, Krakoff I (1987) Phase I trial of caracemide using bolus and infusion schedules. Cancer Treat Rep 71:349–352PubMed

Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750–1757PubMedCrossRef

Raje N, Kumar S, Hideshima T, Ishitsuka K, Yasui H, Chhetri S, Vallet S, Vonescu E, Shiraishi N, Kiziltepe T, Elford HL, Munshi NC, Anderson KC (2006) Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells. Br J Haematol 135:52–61PubMedCrossRef

Ramanathan RK, Fakih M, Mani S, Deutsch M, Perez RP, Ritter MA, Eiseman JL, Ivy SP, Trump DL, Belani CP, Parise RA, Potter DM, Egorin MJ (2006) Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. Cancer Chemother Pharmacol 57:465–474PubMedCrossRef

Raschko JW, Akman SA, Leong LA, Margolin KA, Morgan RJ, Newman E, Somlo G, Ahn C, Doroshow JH (1994) Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea. Cancer Chemother Pharmacol 35:161–164PubMedCrossRef

Ratain MJ, Schilsky RL, Wojack BR, Simon T, Senekjian EK, Vogelzang NJ (1988) Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial. J Natl Cancer Inst 80:1412–1416PubMedCrossRef

Reardon DA, Egorin MJ, Desjardins A, Vredenburgh JJ, Beumer JH, Lagattuta TF, Gururangan S, Herndon JE 2nd, Salvado AJ, Friedman HS (2009) Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer 115:2188–2198PubMedPubMedCentralCrossRef

Reichard P (1993a) The anaerobic ribonucleotide reductase from Escherichia coli. J Biol Chem 268:8383–8386PubMed

Reichard P (1993b) From RNA to DNA, why so many ribonucleotide reductases? Science 260:1773–1777PubMedCrossRef

Riechelmann RP, Townsley CA, Chin SN, Pond GR, Knox JJ (2007) Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 110:1307–1312PubMedCrossRef

Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L, Ceglarek B, Warzocha K, Seferynska I, Piszcz J, Calbecka M, Kostyra A, Dwilewicz-Trojaczek J, Dmoszynska A, Zawilska K, Hellmann A, Zdunczyk A, Potoczek S, Piotrowska M, Lewandowski K, Blonski JZ (2010) Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol 28:1863–1869PubMedCrossRef

Rodriguez GI, Jones RE, Orenberg EK, Stoltz ML, Brooks DJ (2002) Phase I clinical trials of tezacitabine [(E)-2′-deoxy-2′-(fluoromethylene)cytidine] in patients with refractory solid tumors. Clin Cancer Res 8:2828–2834PubMed

Rosen FR, Haraf DJ, Kies MS, Stenson K, Portugal L, List MA, Brockstein BE, Mittal BB, Rademaker AW, Witt ME, Pelzer H, Weichselbaum RR, Vokes EE (2003) Multicenter randomized phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res 9:1689–1697PubMed

Rosenberger G, Fuhrmann G, Grusch M, Fassl S, Elford HL, Smid K, Peters GJ, Szekeres T, Krupitza G (2000) The ribonucleotide reductase inhibitor trimidox induces c-myc and apoptosis of human ovarian carcinoma cells. Life Sci 67:3131–3142PubMedCrossRef

Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM (2009) Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 20:449–453PubMedCrossRef

Rubens RD, Kaye SB, Soukop M, Williams CJ, Brampton MH, Harris AL (1991) Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Br J Cancer 64:1187–1188PubMedPubMedCentralCrossRef

Russo D, Malagola M, de Vivo A, Fiacchini M, Martinelli G, Piccaluga PP, Damiani D, Candoni A, Michielutti A, Castelli M, Testoni N, Ottaviani E, Rondoni M, Pricolo G, Mazza P, Zuffa E, Zaccaria A, Raspadori D, Bocchia M, Lauria F, Bonini A, Avanzini P, Gugliotta L, Visani G, Fanin R, Baccarani M (2005) Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. Br J Haematol 131:172–179PubMedCrossRef

Salama JK, Haraf DJ, Stenson KM, Blair EA, Witt ME, Williams R, Kunnavakkam R, Cohen EE, Seiwert T, Vokes EE (2011) A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol 22(10):2304–2309. doi:10.1093/annonc/mdq736 PubMedCrossRef

Sandler A, Fox S, Meyers T, Christou A, Weber G, Gonin R, Loehrer PJ, Einhorn LH, Dreicer R (1998) Paclitaxel plus gallium nitrate and filgrastim in patients with refractory malignancies: a phase I trial. Am J Clin Oncol 21:180–184PubMedCrossRef

Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122–130PubMedCrossRef

Sanz J, Montesinos P, Saavedra S, Lorenzo I, Senent L, Planelles D, Larrea L, Martin G, Palau J, Jarque I, Martinez J, de la Rubia J, Moscardo F, Martinez D, Gomez I, Lopez M, Sanz MA, Sanz GF (2010) Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia. Biol Blood Marrow Transplant 16:1589–1595PubMedCrossRef

Saven A, Piro LD (1992) Treatment of hairy cell leukemia. Blood 79:1111–1120PubMed

Saven A, Piro LD (1993) 2-Chlorodeoxyadenosine: a new nucleoside agent effective in the treatment of lymphoid malignancies. Leuk Lymphoma 10(Suppl):43–49PubMedCrossRef

Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–3551PubMedCrossRef

Schelman WR, Morgan-Meadows S, Marnocha R, Lee F, Eickhoff J, Huang W, Pomplun M, Jiang Z, Alberti D, Kolesar JM, Ivy P, Wilding G, Traynor AM (2009) A phase I study of triapine in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother Pharmacol 63:1147–1156PubMedCrossRef

Schwartz S, Yagoda A (1984) Phase I–II trial of gallium nitrate for advanced hypernephroma. Anticancer Res 4:317–318PubMed

Sears ME (1964) Phase II studies of hydroxyurea (NSC-32065) in adults: cancer of the breast. Cancer Chemother Rep 40:43PubMed

Seidman AD, Scher HI, Heinemann MH, Bajorin DF, Sternberg CN, Dershaw DD, Silverberg M, Bosl GJ (1991) Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer 68:2561–2565PubMedCrossRef

Seiwert TY, Haraf DJ, Cohen EE, Stenson K, Witt ME, Dekker A, Kocherginsky M, Weichselbaum RR, Chen HX, Vokes EE (2008) Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol 26:1732–1741PubMedCrossRef

Seley KL (2000) Tezacitabine Hoechst Marion Roussel. Curr Opin Investig Drugs 1:135–140PubMed

Senderowicz AM, Reid R, Headlee D, Abornathy T, Horti J, Lush RM, Reed E, Figg WD, Sausville EA (1999) A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer. Urol Int 63:120–125PubMedCrossRef

Shao J, Zhou B, Chu B, Yen Y (2006a) Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 6:409–431PubMedCrossRef

Shao J, Zhou B, Di Bilio AJ, Zhu L, Wang T, Qi C, Shih J, Yen Y (2006b) A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol Cancer Ther 5:586–592PubMedCrossRef

Shao J, Liu X, Zhu L, Yen Y (2013) Targeting ribonucleotide reductase for cancer therapy. Expert Opin Ther Targets 17:1423–1437PubMedCrossRef

Shibata SI, Doroshow JH, Frankel P, Synold TW, Yen Y, Gandara DR, Lenz HJ, Chow WA, Leong LA, Lim D, Margolin KA, Morgan RJ, Somlo G, Newman EM (2009) Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study. Cancer Chemother Pharmacol 64:1149–1155PubMedPubMedCentralCrossRef

Shullenberger CC (1964) Phase II studies of hydroxyurea (NSC-32065) in adults: leukemia. Cancer Chemother Rep 40:49–50PubMed

Sjoberg BM, Reichard P (1977) Nature of the free radical in ribonucleotide reductase from Escherichia coli. J Biol Chem 252:536–541PubMed

Skierski JS, Koronkiewicz M, Grieb P (1999) Effect of FMdC on the cell cycle of some leukemia cell lines. Cytometry 37:302–307PubMedCrossRef

Sridhar SS, Canil CM, Chi KN, Hotte SJ, Ernst S, Wang L, Chen EX, Juhasz A, Yen Y, Murray P, Zwiebel JA, Moore MJ (2011) A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. Cancer Chemother Pharmacol 67:927–933PubMedCrossRef

Stadler WM, Desai AA, Quinn DI, Bukowski R, Poiesz B, Kardinal CG, Lewis N, Makalinao A, Murray P, Torti FM (2008) A phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol 61:689–694PubMedCrossRef

Stehman FB, Bundy BN, Kucera PR, Deppe G, Reddy S, O’Connor DM (1997) Hydroxyurea, 5-fluorouracil infusion, and cisplatin adjunct to radiation therapy in cervical carcinoma: a phase I-II trial of the Gynecologic Oncology Group. Gynecol Oncol 66:262–267PubMedCrossRef

Stolbach LL, Begg CB, Hall T, Horton J (1981) Treatment of renal carcinoma: a phase III randomized trial of oral medroxyprogesterone (Provera), hydroxyurea, and nafoxidine. Cancer Treat Rep 65:689–692PubMed

Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R (1999) An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85:1261–1268PubMedCrossRef

Stubbe J, Riggs-Gelasco P (1998) Harnessing free radicals: formation and function of the tyrosyl radical in ribonucleotide reductase. Trends Biochem Sci 23:438–443PubMedCrossRef

Stubbe J, van Der Donk WA (1998) Protein radicals in enzyme catalysis. Chem Rev 98:705–762PubMedCrossRef

Swinnen LJ, Rankin C, Carraway H, Albain KS, Townsend JJ, Budd GT, Kish JA, Rivkin SE, Blumenthal DT (2008) A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149). J Neurooncol 86:353–358PubMedCrossRef

Szekeres T, Fritzer M, Strobl H, Gharehbaghi K, Findenig G, Elford HL, Lhotka C, Schoen HJ, Jayaram HN (1994a) Synergistic growth inhibitory and differentiating effects of trimidox and tiazofurin in human promyelocytic leukemia HL-60 cells. Blood 84:4316–4321PubMed

Szekeres T, Gharehbaghi K, Fritzer M, Woody M, Srivastava A, van’t Riet B, Jayaram HN, Elford HL (1994b) Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. Cancer Chemother Pharmacol 34:63–66PubMedCrossRef

Szekeres T, Vielnascher E, Novotny L, Vachalkova A, Fritzer M, Findenig G, Gobl R, Elford HL, Goldenberg H (1995) Iron binding capacity of trimidox (3,4,5-trihydroxybenzamidoxime), a new inhibitor of the enzyme ribonucleotide reductase. Eur J Clin Chem Clin Biochem 33:785–789PubMed

Tan BR, Brenner WS, Picus J, Marsh S, Gao F, Fournier C, Fracasso PM, James J, Yen-Revollo JL, McLeod HL (2008) Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies. Ann Oncol 19:1742–1748PubMedCrossRef

Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y (2000) A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404:42–49PubMedCrossRef

Thurman WG, Bloedow C, Howe CD, Levin WC, Davis P, Lane M, Sullivan MP, Griffith KM (1963) A phase I study of hydroxyurea. Cancer Chemother Rep 29:103–107PubMed

Tobinai K, Ogura M, Hotta T, Kobayashi Y, Narabayashi M, Suzuki R, Kinoshita T, Kozuru M, Uike N, Ohashi Y (1997) Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group. Jpn J Clin Oncol 27:146–153PubMedCrossRef

Tobinai K, Ishizawa K, Ogura M, Itoh K, Morishima Y, Ando K, Taniwaki M, Watanabe T, Yamamoto J, Uchida T, Nakata M, Terauchi T, Nawano S, Matsusako M, Hayashi M, Hotta T (2009) Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma. Cancer Sci 100:1951–1956PubMedCrossRef

Tournoux-Facon C, Senellart H, Lemarie E, Tourani JM, Favrel S, Pouget JC, Pinel MC, Bennouna J (2011) Phase I and pharmacokinetic study of IV vinflunine in combination with gemcitabine for treatment of advanced non-small cell lung cancer in chemonaive patients. J Thorac Oncol 6:1247–1253PubMedCrossRef

Traynor AM, Lee JW, Bayer GK, Tate JM, Thomas SP, Mazurczak M, Graham DL, Kolesar JM, Schiller JH (2010) A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: eastern Cooperative Oncology Group Study 1503. Invest New Drugs 28:91–97PubMedCrossRef

Traynor AM, Thomas JP, Ramanathan RK, Mody TD, Alberti D, Wilding G, Bailey HH (2011) Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies. Invest New Drugs 29:316–322PubMedCrossRef

Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O’Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ (2008) Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter’s syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26:196–203PubMedCrossRef

Tu GC, Tu X (2001) GTI-2501. Lorus therapeutics. Curr Opin Investig Drugs 2:1467–1470PubMed

Uhlin U, Eklund H (1994) Structure of ribonucleotide reductase protein R1. Nature 370:533–539PubMedCrossRef

Vallo S, Michaelis M, Rothweiler F, Bartsch G, Gust KM, Limbart DM, Rodel F, Wezel F, Haferkamp A, Cinatl J Jr (2015) Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics. Transl Oncol 8:210–216PubMedPubMedCentralCrossRef

Veale D, Carmichael J, Cantwell BM, Elford HL, Blackie R, Kerr DJ, Kaye SB, Harris AL (1988) A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor. Br J Cancer 58:70–72PubMedPubMedCentralCrossRef

Vokes EE, Panje WR, Schilsky RL, Mick R, Awan AM, Moran WJ, Goldman MD, Tybor AG, Weichselbaum RR (1989) Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I–II study. J Clin Oncol 7:761–768PubMedCrossRef

Wadler S, Haynes H, Schechner R, Rozenblit A, Wiernik PH (1996) Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-alpha-2a in patients with advanced malignancies. Invest New Drugs 13:315–320PubMedCrossRef

Wadler S, Brain C, Catalano P, Einzig AI, Cella D, Benson AB 3rd (2002) Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study E6296. Cancer J 8:282–286PubMedCrossRef

Wakisaka N, Yoshizaki T, Raab-Traub N, Pagano JS (2005) Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts. Int J Cancer 116:640–645PubMedCrossRef

Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C (2008) Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leuk Res 32:1830–1836PubMedCrossRef

Webster LK, Olver IN, Stokes KH, Sephton RG, Hillcoat BL, Bishop JF (2000) A pharmacokinetic and phase II study of gallium nitrate in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 45:55–58PubMedCrossRef

Weissman CH, Reynolds CH, Neubauer MA, Pritchard S, Kobina S, Asmar L (2011) A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 6:358–364PubMedCrossRef

William WN Jr, Zinner RG, Karp DD, Oh YW, Glisson BS, Phan SC, Stewart DJ (2007) Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer. J Thorac Oncol 2:745–750PubMedCrossRef

Witte RS, Hsieh P, Elson P, Oken MM, Trump DL (1996) A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer. Invest New Drugs 14:409–413PubMedCrossRef

Witte RS, Lipsitz S, Goodman TL, Asbury RF, Wilding G, Strnad CM, Smith TJ, Haller DG (1999) A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer. Invest New Drugs 17:173–177PubMedCrossRef

Wright SJ, Robertson LE, O’Brien S, Plunkett W, Keating MJ (1994) The role of fludarabine in hematological malignancies. Blood Rev 8:125–134PubMedCrossRef

Xie KC, Plunkett W (1996) Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl) adenine. Cancer Res 56:3030–3037PubMed

Yamaguchi T, Matsuda K, Sagiya Y, Iwadate M, Fujino MA, Nakamura Y, Arakawa H (2001) p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Can Res 61:8256–8262

Yang SW, Huang P, Plunkett W, Becker FF, Chan JY (1992) Dual mode of inhibition of purified DNA ligase I from human cells by 9-beta-d-arabinofuranosyl-2-fluoroadenine triphosphate. J Biol Chem 267:2345–2349PubMed

Yen Y, Grill SP, Dutschman GE, Chang CN, Zhou BS, Cheng YC (1994) Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. Cancer Res 54:3686–3691PubMed

Zahedi Avval F, Berndt C, Pramanik A, Holmgren A (2009) Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd). Biochem Biophys Res Commun 379:775–779PubMedCrossRef

Zeidner JF, Karp JE, Blackford AL, Smith BD, Gojo I, Gore SD, Levis MJ, Carraway HE, Greer JM, Ivy SP, Pratz KW, McDevitt MA (2014) A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms. Haematologica 99:672–678PubMedPubMedCentralCrossRef

Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, Peng P, Wu X, Lin Q, Xi X, Peng J, Xu M, Chen D, Lu X, Wang R, Cao X, Chen X, Lin Z, Xiong J, Lin Q, Xie C, Li Z, Pan J, Li J, Wu S, Lian Y, Yang Q, Zhao C (2016) Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet 388:1883–1892PubMedCrossRef

Zhou BS, Tsai P, Ker R, Tsai J, Ho R, Yu J, Shih J, Yen Y (1998) Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis 16:43–49PubMedCrossRef

Zinzani PL, Tani M, Pulsoni A, De Renzo A, Stefoni V, Broccoli A, Montini GC, Fina M, Pellegrini C, Gandolfi L, Cavalieri E, Torelli F, Scopinaro F, Argnani L, Quirini F, Derenzini E, Rossi M, Pileri S, Fanti S, Baccarani M (2011) A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. Ann Oncol 23:415–420PubMedCrossRef

Springer Medizin

Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2017

Physical and psychosocial aspects of adolescent and young adults after allogeneic hematopoietic stem-cell transplantation: results from a prospective multicenter trial

Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis

Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway